https://www.selleckchem.com/pr....oducts/Gefitinib.htm
4% had type 2 diabetes. The overall CSCT decreased significantly by -12 m between M0 and M5 (231.7 m at M0 and 219.7 m at M5) ( =0.03). It decreased by -15.2 m ( =0.02) in the aflibercept group (206.9 m at M0 and 191.7 m at M5) and by -7.3 m ( =0.4) in the ranibizumab group (267.5 m at M0 and 260.2 m at M5). The CSCT decreased by -4.9 m in noninjected contralateral eyes (242.3 m at M0 and 237.4 m at M5). CT changes between M0 and M5 in the superior, temporal, inferior, and nasal macular inner ring were significant in the a
Like
Comment
Share
